Table 1 Comparison of clinicopathological features between GADVR tumor thrombus and non-GADVR tumor thrombus
non-GADVR (n = 192) | GADVR (n = 21) | P | |
|---|---|---|---|
Gender, n (%) | 0.988 | ||
Male | 146 (76.0%) | 16 (76.2%) | |
Female | 46 (24.0%) | 5 (23.8%) | |
Age, y, median (IQR) | 60.00 (14.00) | 59.00 (10.00) | 0.550 |
Clinical symptoms, n (%) | 0.068 | ||
No | 50 (26.0%) | 1 (4.8%) | |
Local symptoms | 94 (49.0%) | 16 (76.2%) | |
Systemic symptoms | 12 (6.2%) | 1 (4.8%) | |
Both | 36 (18.8%) | 3 (14.2%) | |
BMI, kg/m2, mean ± SD | 23.87 ± 3.91 | 24.95 ± 2.66 | 0.220 |
Surgical approach, n (%) | 0.035* | ||
Laparoscope | 92 (47.9%) | 5 (23.8%) | |
Open | 100 (52.1%) | 16 (76.2%) | |
Mayo classification, n (%) | 0.093 | ||
0 | 54 (28.1%) | 2 (9.5%) | |
1 | 34 (17.7%) | 3 (14.3%) | |
2 | 70 (36.5%) | 12 (57.2%) | |
3 | 19 (9.9%) | 4 (19.0%) | |
4 | 15 (7.8%) | 0 (0%) | |
IVC segmental resection, n (%) | < 0.001* | ||
No | 162 (84.4%) | 8 (38.1%) | |
Yes | 30 (15.6%) | 13 (61.9%) | |
Preoperative serum creatinine, µmol/L, median (IQR) | 91.00 (27.00) | 110.00 (34.00) | 0.015* |
Serum creatinine 1 week after operation, µmol/L, median (IQR) | 97.00 (33.00) | 96.00 (47.00) | 0.739 |
Side, n (%) | 0.392 | ||
Left | 73 (38.0%) | 10 (47.6%) | |
Right | 119 (62.0%) | 11 (52.4%) | |
Tumor diameter, cm, mean ± SD | 8.94 ± 3.15 | 8.42 ± 2.52 | 0.472 |
Clinical N stage, n (%) | 0.123 | ||
cN0 | 79 (41.1%) | 5 (23.8%) | |
cN1 | 113 (58.9%) | 16 (76.2%) | |
Adrenal metastasis, n (%) | 0.613 | ||
No | 176 (91.7%) | 18 (85.7%) | |
Yes | 16 (8.3%) | 3 (14.3%) | |
Distant metastasis, n (%) | 0.328 | ||
No | 136 (70.8%) | 17 (81.0%) | |
Yes | 56 (29.2%) | 4 (19.0%) | |
Bland thrombus, n (%) | < 0.001* | ||
No | 154 (80.2%) | 9 (42.9%) | |
Yes | 38 (19.8%) | 12 (57.1%) | |
Sarcomatoid feature, n (%) | 1.000 | ||
No | 167 (87.0%) | 18 (85.7%) | |
Yes | 25 (13.0%) | 3 (14.3%) | |
Perirenal fat infiltration, n (%) | 0.728 | ||
No | 130 (67.7%) | 15 (71.4%) | |
Yes | 62 (32.3%) | 6 (28.6%) | |
Pathology type, n (%) | 1.000 | ||
Clear cell RCC | 160 (83.3%) | 17 (81.0%) | |
Non‐clear cell RCC | 32 (16.7%) | 4 (19.0%) | |
Nuclear grade, n (%) | 0.528 | ||
1 | 3 (1.6%) | 0 (0%) | |
2 | 70 (36.4%) | 8 (38.1%) | |
3 | 76 (39.6%) | 11 (52.4%) | |
4 | 43 (22.4%) | 2 (9.5%) | |
Lymph node dissection, n (%) | 0.830 | ||
No | 105 (54.7%) | 12 (57.1%) | |
Yes | 87 (45.3%) | 9 (42.9%) | |
ASA grade, n (%) | 0.816 | ||
1 | 13 (6.8%) | 2 (9.5%) | |
2 | 156 (81.2%) | 17 (81.0%) | |
3 | 23 (12.0%) | 2 (9.5%) | |
Operative time, min, median (IQR) | 308.00 (158.00) | 379.00 (138.00) | 0.038* |
Surgical blood loss, mL, median (IQR) | 600.00 (1550.00) | 1400.00 (850.00) | 0.018* |
Postoperative complication, n (%) | 0.045* | ||
No | 133 (69.3%) | 10 (47.6%) | |
Yes | 59 (30.7%) | 11 (52.4%) | |
Severe postoperative complication, n (%) | 0.912 | ||
No | 180 (93.8%) | 19 (90.5%) | |
Yes | 12 (6.2%) | 2 (9.5%) | |
Thrombus adhering to the IVC, n (%) | 0.002* | ||
No | 104 (54.2%) | 4 (19.0%) | |
Yes | 88 (45.8%) | 17 (81.0%) | |